Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00914641 | Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers | PHASE1 | COMPLETED | 16 | — | — | Jun 1, 2009 | Aug 1, 2009 | Aug 25, 2009 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Apixaban Cross-over | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Apixaban IR | DRUG | immediate release tablet, 10 mg, single dose |
| Apixaban MR1 | DRUG | modified release tablet 1, 10 mg, single dose |
| Apixaban MR2 | DRUG | modified release tablet 2, 10 mg, single dose |
| Apixaban MR3 | DRUG | modified release tablet 3, 10 mg, single dose |
Inclusion Criteria: * Healthy male or female patients * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 Exclusion Criteria: * Any condition possibly affecting drug absorption * History or evidence of abnormal bleeding or clotting disorder